دورية أكاديمية
أعرض في EDS

Targeting HIV persistence in the tissue.

التفاصيل البيبلوغرافية
العنوان: Targeting HIV persistence in the tissue.
المؤلفون: Pieren DKJ; Infectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Benítez-Martínez A, Genescà M
المصدر: Current opinion in HIV and AIDS [Curr Opin HIV AIDS] 2024 Mar 01; Vol. 19 (2), pp. 69-78. Date of Electronic Publication: 2024 Jan 08.
نوع المنشور: Review; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101264945 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1746-6318 (Electronic) Linking ISSN: 1746630X NLM ISO Abbreviation: Curr Opin HIV AIDS Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, c2006-
مواضيع طبية MeSH: HIV Infections*/drug therapy, Humans ; Virus Latency ; CD4-Positive T-Lymphocytes
مستخلص: Purpose of Review: The complex nature and distribution of the HIV reservoir in tissue of people with HIV remains one of the major obstacles to achieve the elimination of HIV persistence. Challenges include the tissue-specific states of latency and viral persistence, which translates into high levels of reservoir heterogeneity. Moreover, the best strategies to reach and eliminate these reservoirs may differ based on the intrinsic characteristics of the cellular and anatomical reservoir to reach.
Recent Findings: While major focus has been undertaken for lymphoid tissues and follicular T helper cells, evidence of viral persistence in HIV and non-HIV antigen-specific CD4 + T cells and macrophages resident in multiple tissues providing long-term protection presents new challenges in the quest for an HIV cure. Considering the microenvironments where these cellular reservoirs persist opens new venues for the delivery of drugs and immunotherapies to target these niches. New tools, such as single-cell RNA sequencing, CRISPR screenings, mRNA technology or tissue organoids are quickly developing and providing detailed information about the complex nature of the tissue reservoirs.
Summary: Targeting persistence in tissue reservoirs represents a complex but essential step towards achieving HIV cure. Combinatorial strategies, particularly during the early phases of infection to impact initial reservoirs, capable of reaching and reactivating multiple long-lived reservoirs in the body may lead the path.
(Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.)
References: Chaillon A, Gianella S, Dellicour S, et al. HIV persists throughout deep tissues with repopulation from multiple anatomical sources. J Clin Invest 2020; 130:1699–1712.
De Scheerder MA, Vrancken B, Dellicour S, et al. HIV rebound is predominantly fueled by genetically identical viral expansions from diverse reservoirs. Cell Host Microbe 2019; 26:347–358. e7.
Sun W, Rassadkina Y, Gao C, et al. Persistence of intact HIV-1 proviruses in the brain during antiretroviral therapy. Elife 2023; 12:RP89837.
Cole B, Lambrechts L, Boyer Z, et al. Extensive characterization of HIV-1 reservoirs reveals links to plasma viremia before and during analytical treatment interruption. Cell Rep 2022; 39:110739.
Gantner P, Buranapraditkun S, Pagliuzza A, et al. HIV rapidly targets a diverse pool of CD4(+) T cells to establish productive and latent infections. Immunity 2023; 56:653–668. e5.
Shahid A, MacLennan S, Jones BR, et al. The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time. Res Square 2023; doi: 10.21203/rs.3.rs-3259040/v1. (PMID: 10.21203/rs.3.rs-3259040/v1)
Tokarev A, Machmach K, Creegan M, et al. Single-cell profiling of latently SIV-infected CD4(+) T cells directly ex vivo to reveal host factors supporting reservoir persistence. Microbiol Spectrum 2022; 10:e0060422.
Abrahams MR, Joseph SB, Garrett N, et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci Transl Med 2019; 11:eaaw5589.
Cantero-Perez J, Grau-Exposito J, Serra-Peinado C, et al. Resident memory T cells are a cellular reservoir for HIV in the cervical mucosa. Nat Commun 2019; 10:4739.
Ganor Y, Real F, Sennepin A, et al. HIV-1 reservoirs in urethral macrophages of patients under suppressive antiretroviral therapy. Nat Microbiol 2019; 4:633–644.
Packard TA, Schwarzer R, Herzig E, et al. CCL2: a chemokine potentially promoting early seeding of the latent HIV Reservoir. mBio 2022; 13:e0189122.
Kunzli M, Masopust D. CD4(+) T cell memory. Nat Immunol 2023; 24:903–914.
Poon MML, Caron DP, Wang Z, et al. Tissue adaptation and clonal segregation of human memory T cells in barrier sites. Nat Immunol 2023; 24:309–319.
Genesca M, Skinner PJ, Bost KM, et al. Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol 2008; 1:219–228.
Lisco A, Lange C, Manion M, et al. Immune reconstitution inflammatory syndrome drives emergence of HIV drug resistance from multiple anatomic compartments in a person living with HIV. Nat Med 2023; 29:1364–1369.
Reeves DB, Bacchus-Souffan C, Fitch M, et al. Estimating the contribution of CD4 T cell subset proliferation and differentiation to HIV persistence. Nat Commun 2023; 14:6145.
Bosque A, Famiglietti M, Weyrich AS, et al. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Pathogens 2011; 7:e1002288.
Chomont N, DaFonseca S, Vandergeeten C, et al. Maintenance of CD4+ T-cell memory and HIV persistence: keeping memory, keeping HIV. Curr Opin HIV AIDS 2011; 6:30–36.
Simonetti FR, Zhang H, Soroosh GP, et al. Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo. J Clin Invest 2021; 131:e145254.
Vandergeeten C, Fromentin R, DaFonseca S, et al. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013; 121:4321–4329.
Dufour C, Richard C, Pardons M, et al. Phenotypic characterization of single CD4+ T cells harboring genetically intact and inducible HIV genomes. Nat Commun 2023; 14:1115.
Clark IC, Mudvari P, Thaploo S, et al. HIV silencing and cell survival signatures in infected T cell reservoirs. Nature 2023; 614:318–325.
Sun W, Gao C, Hartana CA, et al. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature 2023; 614:309–317.
Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009; 15:893–900.
Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013; 210:143–156.
Wu VH, Nordin JML, Nguyen S, et al. Profound phenotypic and epigenetic heterogeneity of the HIV-1-infected CD4(+) T cell reservoir. Nat Immunol 2023; 24:359–370.
Astorga-Gamaza A, Grau-Exposito J, Burgos J, et al. Identification of HIV-reservoir cells with reduced susceptibility to antibody-dependent immune response. eLife 2022; 11:e78294.
Clain JA, Rabezanahary H, Racine G, et al. Early ART reduces viral seeding and innate immunity in liver and lungs of SIV-infected macaques. JCI insight 2023; 8:e167856.
Veenhuis RT, Abreu CM, Costa PAG, et al. Monocyte-derived macrophages contain persistent latent HIV reservoirs. Nat Microbiol 2023; 8:833–844.
Ng LG, Liu Z, Kwok I, Ginhoux F. Origin and heterogeneity of tissue myeloid cells: a focus on GMP-derived monocytes and neutrophils. Annu Rev Immunol 2023; 41:375–404.
Real F, Zhu A, Huang B, et al. S100A8-mediated metabolic adaptation controls HIV-1 persistence in macrophages in vivo. Nat Commun 2022; 13:5956.
Otte F, Zhang Y, Spagnuolo J, et al. Revealing viral and cellular dynamics of HIV-1 at the single-cell level during early treatment periods. Cell Rep Methods 2023; 3:100485.
Baiyegunhi OO, Mann J, Khaba T, et al. CD8 lymphocytes mitigate HIV-1 persistence in lymph node follicular helper T cells during hyperacute-treated infection. Nat Commun 2022; 13:4041.
Dufour C, Ruiz MJ, Pagliuzza A, et al. Near full-length HIV sequencing in multiple tissues collected postmortem reveals shared clonal expansions across distinct reservoirs during ART. Cell reports 2023; 42:113053.
Collins DR, Hitschfel J, Urbach JM, et al. Cytolytic CD8(+) T cells infiltrate germinal centers to limit ongoing HIV replication in spontaneous controller lymph nodes. Sci Immunol 2023; 8:eade5872.
Ugur M, Schulz O, Menon MB, et al. Resident CD4+ T cells accumulate in lymphoid organs after prolonged antigen exposure. Nat Commun 2014; 5:4821.
Pampusch MS, Abdelaal HM, Cartwright EK, et al. CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection. PLoS Pathogens 2022; 18:e1009831.
Rahman SA, Billingsley JM, Sharma AA, et al. Lymph node CXCR5+ NK cells associate with control of chronic SHIV infection. JCI insight 2022; 7:e155601.
Rascle P, Jacquelin B, Petitdemange C, et al. NK-B cell cross talk induces CXCR5 expression on natural killer cells. iScience 2021; 24:103109.
Harper J, Huot N, Micci L, et al. IL-21 and IFNalpha therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques. Nat Commun 2021; 12:2866.
Yim LY, Lam KS, Luk TY, et al. Transforming growth factor beta signaling promotes HIV-1 infection in activated and resting memory CD4(+) T cells. J Virol 2023; 97:e0027023.
Samer S, Thomas Y, Arainga M, et al. Blockade of TGF-beta signaling reactivates HIV-1/SIV reservoirs and immune responses in vivo. JCI Insight 2022; 7:.
Ogunshola FJ, Smidt W, Naidoo AF, et al. Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8+ T cells into B-cell follicles during HIV-1 infection. Blood Adv 2022; 6:1904–1916.
Jiang S, Chan CN, Rovira-Clave X, et al. Combined protein and nucleic acid imaging reveals virus-dependent B cell and macrophage immunosuppression of tissue microenvironments. Immunity 2022; 55:1118–1134. e8.
Harper J, Ribeiro SP, Chan CN, et al. Interleukin-10 contributes to reservoir establishment and persistence in SIV-infected macaques treated with antiretroviral therapy. J Clin Invest 2022; 132:.
Chun TW, Nickle DC, Justement JS, et al. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis 2008; 197:714–720.
Asowata OE, Singh A, Ngoepe A, et al. Irreversible depletion of intestinal CD4+ T cells is associated with T cell activation during chronic HIV infection. JCI Insight 2021; 6:e146162.
McElrath MJ, Smythe K, Randolph-Habecker J, et al. Comprehensive assessment of HIV target cells in the distal human gut suggests increasing HIV susceptibility toward the anus. J Acquir Immune Defic Syndr 2013; 63:263–271.
Sainz T, Serrano-Villar S, Mann S, et al. Delayed gastrointestinal-associated lymphoid tissue reconstitution in duodenum compared with rectum in HIV-infected patients initiating antiretroviral therapy. AIDS 2019; 33:2289–2298.
Wiche Salinas TR, Zhang Y, Sarnello D, et al. Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth. Proc Natl Acad Sci USA 2021; 118:e2105927118.
Nayrac M, Requena M, Loiseau C, et al. Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals. Mucosal Immunol 2021; 14:219–228.
Anderson JL, Khoury G, Fromentin R, et al. Human immunodeficiency virus (HIV)-infected CCR6+ rectal CD4+ T cells and HIV persistence on antiretroviral therapy. J Infect Dis 2020; 221:744–755.
Velarde de la Cruz E, Wang L, Bose D, et al. Oral vaccination approaches for anti-SHIV immunity. Front Immunol 2021; 12:702705.
Strongin Z, Hoang TN, Tharp GK, et al. The role of CD101-expressing CD4 T cells in HIV/SIV pathogenesis and persistence. PLoS Pathogens 2022; 18:e1010723.
Allers K, Fehr M, Conrad K, et al. Macrophages accumulate in the gut mucosa of untreated HIV-infected patients. J Infect Dis 2014; 209:739–748.
Zalar A, Figueroa MI, Ruibal-Ares B, et al. Macrophage HIV-1 infection in duodenal tissue of patients on long term HAART. Antiviral Res 2010; 87:269–271.
Takahashi N, Sugimoto C, Allers C, et al. Shifting dynamics of intestinal macrophages during simian immunodeficiency virus infection in adult rhesus macaques. J Immunol 2019; 202:2682–2689.
Sneller MC, Clarridge KE, Seamon C, et al. An open-label phase 1 clinical trial of the antialpha(4)beta(7) monoclonal antibody vedolizumab in HIV-infected individuals. Science Transl Med 2019; 11:eaax3447.
Johnson SD, Knight LA, Kumar N, et al. Early treatment with antialpha(4)beta(7) antibody facilitates increased gut macrophage maturity in SIV-infected rhesus macaques. Front Immunol 2022; 13:1001727.
Planas D, Pagliuzza A, Ponte R, et al. LILAC pilot study: effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy. EBioMedicine 2021; 65:103270.
Wahl A, Yao W, Liao B, et al. A germ-free humanized mouse model shows the contribution of resident microbiota to human-specific pathogen infection. Nat Biotechnol 2023; doi: 10.1038/s41587-023-01906-5. [Online ahead of print]. (PMID: 10.1038/s41587-023-01906-5.)
Serrano-Villar S, Talavera-Rodriguez A, Gosalbes MJ, et al. Fecal microbiota transplantation in HIV: a pilot placebo-controlled study. Nat Commun 2021; 12:1139.
Honeycutt JB, Liao B, Nixon CC, et al. T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest 2018; 128:2862–2876.
Lutgen V, Narasipura SD, Barbian HJ, et al. HIV infects astrocytes in vivo and egresses from the brain to the periphery. PLoS Pathog 2020; 16:e1008381.
Torices S, Teglas T, Naranjo O, et al. Occludin regulates HIV-1 infection by modulation of the interferon stimulated OAS gene family. Mol Neurobiol 2023; 60:4966–4982.
Nuhn MM, Gumbs SBH, Buchholtz N, et al. Shock and kill within the CNS: A promising HIV eradication approach? J Leukoc Biol 2022; 112:1297–1315.
Cochrane CR, Angelovich TA, Byrnes SJ, et al. Intact HIV proviruses persist in the brain despite viral suppression with ART. Ann Neurol 2022; 92:532–544.
Gabuzda D, Yin J, Misra V, et al. Intact proviral DNA analysis of the brain viral reservoir and relationship to neuroinflammation in people with HIV on suppressive antiretroviral therapy. Viruses 2023; 15:1009.
Angelovich TA, Cochrane CR, Zhou J, et al. Regional analysis of intact and defective HIV proviruses in the brain of viremic and virally suppressed people with HIV. Ann Neurol 2023; 94:798–802.
Tang Y, Chaillon A, Gianella S, et al. Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy. J Clin Invest 2023; 133:e167417.
Rose R, Gonzalez-Perez MP, Nolan D, et al. Distinct HIV-1 population structure across meningeal and peripheral T cells and macrophage lineage cells. Microbiol Spectrum 2022; 10:e0250822.
Kakad SP, Gangurde TD, Kshirsagar SJ, Mundhe VG. Nose to brain delivery of nanosuspensions with first line antiviral agents is alternative treatment option to Neuro-AIDS treatment. Heliyon 2022; 8:e09925.
Wu DD, Salah YA, Ngowi EE, et al. Nanotechnology prospects in brain therapeutics concerning gene-targeting and nose-to-brain administration. iScience 2023; 26:107321.
Gong Y, Chowdhury P, Nagesh PKB, et al. Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages. Sci Rep 2020; 10:3835.
Zhao Z, Ukidve A, Kim J, Mitragotri S. Targeting strategies for tissue-specific drug delivery. Cell 2020; 181:151–167.
Gumbs SBH, Berdenis van Berlekom A, Kubler R, et al. Characterization of HIV-1 infection in microglia-containing human cerebral organoids. Viruses 2022; 14:829.
Boucher T, Liang S, Brown AM. Advancing basic and translational research to deepen understanding of the molecular immune-mediated mechanisms regulating long-term persistence of HIV-1 in microglia in the adult human brain. J Leukoc Biol 2022; 112:1223–1231.
Wong JK, Yukl SA. Tissue reservoirs of HIV. Curr Opin HIV AIDS 2016; 11:362–370.
Liu Z, Julius P, Kang G, et al. Subtype C HIV-1 reservoirs throughout the body in ART-suppressed individuals. JCI Insight 2022; 7:e162604.
Zerbato JM, Avihingsanon A, Singh KP, et al. HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapy. EBioMedicine 2023; 87:104391.
Shahid A, Jones BR, Yang JSW, et al. HIV proviral genetic diversity, compartmentalization and inferred dynamics in lung and blood during long-term suppressive antiretroviral therapy. PLoS Pathogens 2022; 18:e1010613.
Renelt S, Schult-Dietrich P, Baldauf HM, et al. HIV-1 infection of long-lived hematopoietic precursors in vitro and in vivo. Cells 2022; 11:2968.
Zaikos TD, Terry VH, Sebastian Kettinger NT, et al. Hematopoietic stem and progenitor cells are a distinct HIV reservoir that contributes to persistent viremia in suppressed patients. Cell Rep 2018; 25:3759–3773. e9.
Baker EJ, Hughes K, Travieso T, et al. Establishment, persistence, and reactivation of latent HIV-1 infection in renal epithelial cells. J Virol 2022; 96:e0062422.
Routy JP, Dupuy FP, Lin J, Isnard S. More than a gender issue: testis as a distinctive HIV reservoir and its implication for viral eradication. Methods Mol Biol 2022; 2407:173–186.
Sereme Y, Polvora TLS, Rochereau N, et al. Gingival tissue as a reservoir for human immunodeficiency virus type 1: preliminary results of a cross-sectional observational study. J Periodontol 2022; 93:613–620.
Jiang G, Maverakis E, Cheng MY, et al. Disruption of latent HIV in vivo during the clearance of actinic keratosis by ingenol mebutate. JCI Insight 2019; 4:e126027.
Saluzzo S, Pandey RV, Gail LM, et al. Delayed antiretroviral therapy in HIV-infected individuals leads to irreversible depletion of skin- and mucosa-resident memory T cells. Immunity 2021; 54:2842–2858. e5.
Gondim MVP, Sherrill-Mix S, Bibollet-Ruche F, et al. Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. Sci Transl Med 2021; 13:eabd8179.
White JA, Wu F, Yasin S, et al. Clonally expanded HIV-1 proviruses with 5’-leader defects can give rise to nonsuppressible residual viremia. J Clin Invest 2023; 133:e165245.
Board NL, Moskovljevic M, Wu F, et al. Engaging innate immunity in HIV-1 cure strategies. Nat Rev Immunol 2022; 22:499–512.
Grau-Exposito J, Luque-Ballesteros L, Navarro J, et al. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. PLoS Pathogens 2019; 15:e1007991.
Riddler SA, Para M, Benson CA, et al. Vesatolimod, a Toll-like receptor 7 agonist, induces immune activation in virally suppressed adults living with human immunodeficiency virus-1. Clin Infect Dis 2021; 72:e815–e824.
SenGupta D, Brinson C, DeJesus E, et al. The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. Sci Transl Med 2021; 13:eabg3071.
Walker-Sperling VEK, Mercado NB, Chandrashekar A, et al. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques. Nat Commun 2022; 13:3463.
Gunst JD, Hojen JF, Pahus MH, et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat Med 2023; 29:2547–2558.
Amand M, Adams P, Schober R, et al. The anticaspase 1 inhibitor VX-765 reduces immune activation, CD4(+) T cell depletion, viral load, and total HIV-1 DNA in HIV-1 infected humanized mice. eLife 2023; 12:e83207.
Nixon CC, Mavigner M, Sampey GC, et al. Systemic HIV and SIV latency reversal via noncanonical NF-kappaB signalling in vivo. Nature 2020; 578:160–165.
Rubione J, Perez PS, Czernikier A, et al. A dynamic interplay of circulating extracellular vesicles and galectin-1 reprograms viral latency during HIV-1 infection. mBio 2022; 13:e0061122.
Hokello J, Lakhikumar Sharma A, Tyagi M. AP-1 and NF-kappaB synergize to transcriptionally activate latent HIV upon T-cell receptor activation. FEBS Lett 2021; 595:577–594.
Stevenson EM, Terry S, Copertino D, et al. SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8(+) T-cells. Nat Commun 2022; 13:4888.
Pieren DKJ, Kuguel SG, Rosado J, et al. Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection. Nat Commun 2023; 14:1887.
Cohen KW, De Rosa SC, Fulp WJ, et al. A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses. Sci Transl Med 2023; 15:eadf3309.
Leggat DJ, Cohen KW, Willis JR, et al. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 2022; 378:eadd6502.
Dai W, Wu F, McMyn N, et al. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir. Sci Transl Med 2022; 14:eabh3351.
Chatterjee D, Zhang Y, Ngassaki-Yoka CD, et al. Identification of aryl hydrocarbon receptor as a barrier to HIV-1 infection and outgrowth in CD4(+) T cells. Cell Rep 2023; 42:112634.
Kim JT, Zhang TH, Carmona C, et al. Latency reversal plus natural killer cells diminish HIV reservoir in vivo. Nat Commun 2022; 13:121.
Promsote W, Xu L, Hataye J, et al. Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections. Nat Commun 2023; 14:3719.
Miller JS, Davis ZB, Helgeson E, et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat Med 2022; 28:392–400.
Chen M, Li M, Budai MM, et al. Clearance of HIV-1 or SIV reservoirs by promotion of apoptosis and inhibition of autophagy: Targeting intracellular molecules in cure-directed strategies. J Leukoc Biol 2022; 112:1245–1259.
Freeman TL, Zhao C, Schrode N, et al. HIV-1 activates oxidative phosphorylation in infected CD4 T cells in a human tonsil explant model. Front Immunol 2023; 14:1172938.
Guo H, Wang Q, Ghneim K, et al. Multiomics analyses reveal that HIV-1 alters CD4(+) T cell immunometabolism to fuel virus replication. Nat Immunol 2021; 22:423–433.
Pan Y, Tian T, Park CO, et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature 2017; 543:252–256.
Phan AT, Doedens AL, Palazon A, et al. Constitutive glycolytic metabolism supports CD8(+) T cell effector memory differentiation during viral infection. Immunity 2016; 45:1024–1037.
Valle-Casuso JC, Angin M, Volant S, et al. Cellular metabolism is a major determinant of HIV-1 reservoir seeding in CD4(+) T cells and offers an opportunity to tackle infection. Cell Metab 2019; 29:611–626. e5.
Wculek SK, Heras-Murillo I, Mastrangelo A, et al. Oxidative phosphorylation selectively orchestrates tissue macrophage homeostasis. Immunity 2023; 56:516–530. e9.
Castellano P, Prevedel L, Valdebenito S, Eugenin EA. HIV infection and latency induce a unique metabolic signature in human macrophages. Sci Rep 2019; 9:3941.
Gianella S, Rawlings SA, Dobrowolski C, et al. Sex differences in human immunodeficiency virus persistence and reservoir size during aging. Clin Infect Dis 2022; 75:73–80.
Scully EP, Aga E, Tsibris A, et al. Impact of tamoxifen on vorinostat-induced human immunodeficiency virus expression in women on antiretroviral therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clin Infect Dis 2022; 75:1389–1396.
Margolis DM, Archin NM, Cohen MS, et al. Curing HIV: seeking to target and clear persistent infection. Cell 2020; 181:189–206.
تواريخ الأحداث: Date Created: 20240103 Date Completed: 20240206 Latest Revision: 20240603
رمز التحديث: 20240603
DOI: 10.1097/COH.0000000000000836
PMID: 38169333
قاعدة البيانات: MEDLINE
الوصف
تدمد:1746-6318
DOI:10.1097/COH.0000000000000836